Read by QxMD icon Read


Grandhi Venkata Ramalingayya, Sri Pragnya Cheruku, Pawan G Nayak, Anoop Kishore, Rekha Shenoy, Chamallamudi Mallikarjuna Rao, Nandakumar Krishnadas
Doxorubicin (DOX) is the most widely used broad-spectrum anticancer agent, either alone or in combination, for most cancers including breast cancer. Long-term use of chemotherapeutic agents to treat breast cancer patients results in cognitive complications with a negative impact on survivors' quality of life. The study objective was to evaluate rutin (RUT) for its neuroprotective effect against DOX in human neuroblastoma (IMR32) cells in vitro and study its potential to ameliorate DOX-induced cognitive dysfunction in Wistar rats...
2017: Drug Design, Development and Therapy
Michael J Sofis, David P Jarmolowicz, Sam V Kaplan, Rachel C Gehringer, Shea M Lemley, Brian S Blagg, Michael A Johnson
Chemotherapy induced cognitive impairment (i.e. Chemobrain) involves acute and long-term deficits in memory, executive function, and processing speed. Animal studies investigating these cognitive deficits have had mixed results, potentially due to variability in the complexity of behavioral tasks across experiments. Further, common chemotherapy treatments such as 5-Fluorouracil (5-FU) break down myelin integrity corresponding to hippocampal neurodegenerative deficits and mitochondrial dysfunction. There is little evidence, however, of pharmacological treatments that may target mitochondrial dysfunction...
March 27, 2017: Behavioural Brain Research
Flavie Bompaire, Thomas Durand, Isabelle Léger-Hardy, Dimitri Psimaras, Damien Ricard
Cognitive complaints are frequent in patients who received chemotherapy for a non-CNS cancer. These observations have been described as « chemobrain ». However, studies results are contradictory concerning the implication of chemotherapy in the onset of cognitive defects. Moreover, other factors as mood, anxiety and fatigue are often associated in this population and could be confounding. This article present principal results of research in human experiencing chemobrain, concerning clinical presentation, neuropsychological examination, imaging techniques and treatment possibilities...
March 1, 2017: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
Gabriel S Chiu, Magdalena A Maj, Sahar Rizvi, Robert Dantzer, Elisabeth G Vichaya, Geoffroy Laumet, Annemieke Kavelaars, Cobi J Heijnen
Cognitive impairment, termed chemobrain, is a common neurotoxicity associated with chemotherapy treatment, affecting an estimated 78% of patients. Prompted by the hypothesis that neuronal mitochondrial dysfunction underlies chemotherapy-induced cognitive impairment (CICI), we explored the efficacy of administering the small-molecule pifithrin (PFT)-μ, an inhibitor of mitochondrial p53 accumulation, in preventing CICI. Male C57BL/6J mice injected with cisplatin ± PFT-μ for two 5-day cycles were assessed for cognitive function using novel object/place recognition and alternation in a Y-maze...
February 1, 2017: Cancer Research
Alexandre Iarkov, Doreen Appunn, Valentina Echeverria
PURPOSE: Most cancer patients treated with systemic adjuvant chemotherapy endure long-lasting side effects including decrease in concentration, forgetfulness and slower thinking, which are globally termed "chemobrain." Cotinine, the main derivative of nicotine, improved visual and spatial working memory and decreased depressive-like behavior in an animal model of chemotherapy-induced cognitive impairment. METHODS: In this study, we investigated the effect of cotinine on weight gain, locomotor activity, cognitive abilities and depressive-like behavior in rats treated with the chemotherapy mix, cyclophosphamide, methotrexate and 5-fluorouracil...
October 5, 2016: Cancer Chemotherapy and Pharmacology
Ilhan Lim, Hye-Young Joung, A Ram Yu, Insop Shim, Jin Su Kim
A considerable number of patients with breast cancer complain of cognitive impairment after chemotherapy. In this study, we showed that donepezil enhanced memory function and increased brain glucose metabolism in a rat model of cognitive impairment after chemotherapy using behavioral analysis and positron emission tomography (PET). We found that chemotherapy affected spatial learning ability, reference memory, and working memory and that donepezil improved these cognitive impairments. According to PET analysis, chemotherapy reduced glucose metabolism in the medial prefrontal cortex and hippocampus, and donepezil increased glucose metabolism in the bilateral frontal lobe, parietal lobe, and hippocampus...
2016: BioMed Research International
Amelia Maria Gaman, Adriana Uzoni, Aurel Popa-Wagner, Anghel Andrei, Eugen-Bogdan Petcu
Chemobrain or chemotherapy induced cognitive impairment (CICI) represents a new clinical syndrome characterised by memory, learning and motor function impairment. As numerous patients with cancer are long-term survivors, CICI represent a significant factor which may interfere with their quality of life. However, this entity CICI must be distinguished from other cognitive syndromes and addressed accordingly. At the present time, experimental and clinical research suggests that CICI could be induced by numerous factors including oxidative stress...
May 2016: Aging and Disease
Grandhi Venkata Ramalingayya, Pawan G Nayak, Rekha R Shenoy, Chamallamudi Mallikarjuna Rao, Krishnadas Nandakumar
No abstract text is available yet for this article.
September 2016: Clinical and Experimental Pharmacology & Physiology
Sam V Kaplan, Ryan A Limbocker, Rachel C Gehringer, Jenny L Divis, Gregory L Osterhaus, Maxwell D Newby, Michael J Sofis, David P Jarmolowicz, Brooke D Newman, Tiffany A Mathews, Michael A Johnson
Chemotherapy-induced cognitive impairment, known also as "chemobrain", is a medical complication of cancer treatment that is characterized by a general decline in cognition affecting visual and verbal memory, attention, complex problem solving skills, and motor function. It is estimated that one-third of patients who undergo chemotherapy treatment will experience cognitive impairment. Alterations in the release and uptake of dopamine and serotonin, central nervous system neurotransmitters that play important roles in cognition, could potentially contribute to impaired intellectual performance in those impacted by chemobrain...
June 15, 2016: ACS Chemical Neuroscience
Grandhi Venkata Ramalingayya, Madhavan Nampoothiri, Pawan G Nayak, Anoop Kishore, Rekha R Shenoy, Chamallamudi Mallikarjuna Rao, Krishnadas Nandakumar
BACKGROUND: Cognitive decline or dementia is a debilitating problem of neurological disorders such as Alzheimer's and Parkinson's disease, including special conditions like chemobrain. Dietary flavonoids proved to be efficacious in delaying the incidence of neurodegenerative diseases. Two such flavonoids, naringin (NAR) and rutin (RUT) were reported to have neuroprotective potential with beneficial effects on spatial and emotional memories in particular. However, the efficacy of these flavonoids is poorly understood on episodic memory, which comprises an important form of autobiographical memory...
January 2016: Pharmacognosy Magazine
Wenjun Zhou, Annemieke Kavelaars, Cobi J Heijnen
RATIONALE: Chemotherapy-induced cognitive impairment, also known as 'chemobrain', is now widely recognized as a frequent adverse side effect of cancer treatment that often persists into survivorship. There are no drugs available to prevent or treat chemotherapy-induced cognitive deficits. The aim of this study was to establish a mouse model of cisplatin-induced cognitive deficits and to determine the potential preventive effects of the anti-diabetic drug metformin. RESULTS: Treatment of C57/BL6J mice with cisplatin (cumulative dose 34...
2016: PloS One
Grandhi Venkata Ramalingayya, Karthik Gourishetti, Anoop Kishore, Krishnadas Nandakumar
No abstract text is available yet for this article.
June 2016: Clinical and Experimental Pharmacology & Physiology
Dénes Kleiner, Ágnes Szilvás, Klára Szentmihályi, Krisztina Süle, Anna Blázovics
Nowadays it has been established that metals and metal-induced oxidative stress act on signal transduction pathways, and are in association with cancer growth and spreading as well as in neurodegenerative disorders. In cases of several neurodegenerative diseases metals, especially Al, can be considered as a risk factor. Frequency of chemotherapy-related cognitive impairment or "chemobrain" is mentioned to be significant in literature, although very little is known about the chemotherapy-caused chemobrain and its connection with metal homeostasis alteration...
January 2016: Journal of Trace Elements in Medicine and Biology
Diane F Morean, Linda O'Dwyer, Leora R Cherney
OBJECTIVE: To systematically review evidence of treatments for cognitive impairments experienced by at least 20% of all women who undergo chemotherapy for breast cancer. DATA SOURCES: Searches of 5 databases (PubMed, Embase, Cochrane CENTRAL, PsycINFO, CINAHL), with no date or language restrictions, identified 1701 unique results. Search terms included breast cancer, chemotherapy, chemobrain, chemofog, and terms on cognition and language deficits. STUDY SELECTION: Included only peer-reviewed journal articles that described therapies for cognitive dysfunction in women undergoing (or who had undergone) chemotherapy for breast cancer and provided objective measurements of cognition or language...
October 2015: Archives of Physical Medicine and Rehabilitation
Akina Natori, Toru Ogata, Hideko Yamauchi
No abstract text is available yet for this article.
May 2015: Aging
Charlotte K Callaghan, Shane M O'Mara
Clinical studies report evidence of long-term cognitive and other deficits following adjunctive chemotherapy treatment, which is often termed "chemobrain" or "chemo-fog". The neurological bases of these impairments are poorly understood. Here, we hypothesize that systemic chemotherapy treatment causes long-term neurobehavioral deficits, and that these deficits are reversed by manipulation of cAMP by the PDE4 inhibitor, rolipram. Male han Wistar rats were treated with docetaxel (an adjunctive chemotherapeutic agent (1mg/kg i...
September 1, 2015: Behavioural Brain Research
Brent J Small, Stacey B Scott, Heather S L Jim, Paul B Jacobsen
With advances in screening and early detection, coupled with improved treatment and care, the number of cancer survivors has risen exponentially over the past several decades. Moreover, because age is the most significant risk factor for cancer, the majority of cancer survivors are over 65 years of age. Finally, cancer survivors often experience significant health issues for many years after the treatment has subsided. In the current article, we describe select research that has focused on changes to cognitive performance associated with cancer and its treatment, i...
2015: Gerontology
Munjal M Acharya, Vahan Martirosian, Nicole N Chmielewski, Nevine Hanna, Katherine K Tran, Alicia C Liao, Lori-Ann Christie, Vipan K Parihar, Charles L Limoli
The frequent use of chemotherapy to combat a range of malignancies can elicit severe cognitive dysfunction often referred to as "chemobrain," a condition that can persist long after the cessation of treatment in as many as 75% of survivors. Although cognitive health is a critical determinant of therapeutic outcome, chemobrain remains an unmet medical need that adversely affects quality of life in pediatric and adult cancer survivors. Using a rodent model of chemobrain, we showed that chronic cyclophosphamide treatment induced significant performance-based decrements on behavioral tasks designed to interrogate hippocampal and cortical function...
February 15, 2015: Cancer Research
(no author information available yet)
[This corrects the article DOI: 10.1371/journal.pone.0108002.].
2015: PloS One
Xiao-Min Wang, Brian Walitt, Leorey Saligan, Agnes F Y Tiwari, Chi Wai Cheung, Zhang-Jin Zhang
One consequence of modern cancer therapy is chemotherapy related cognitive dysfunction or "chemobrain", the subjective experience of cognitive deficits at any point during or following chemotherapy. Chemobrain, a well-established clinical syndrome, has become an increasing concern because the number of long-term cancer survivors is growing dramatically. There is strong evidence that correlates changes in peripheral cytokines with the development of chemobrain in commonly used chemotherapeutic drugs for different types of cancer...
March 2015: Cytokine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"